NeuExcell Starts Trial of Gene Therapy to Create Neurons for Glioblastoma

Suzhou NeuExcell Therapeutics, a company focused on in vivo neural regenerative therapies, dosed the first patient with a first-in-class NeuroD1 gene therapy product NXL-004. The company explains that neural tissues contain two major types of cells: neurons and supportive glial cells such as astrocytes. Although neurons cannot divide or replenish themselves, glial cells can.  Because both are derived from neural stem cells, neurons and astrocytes have many similar traits. NeuExcell applies its astrocyte-to-neuron (AtN) conversion technology to replace dead neurons in diseased or injured tissues. The investigator trial will evaluate NXL-004 in patients with glioblastoma. More details....

Share this with colleagues: